Fondaparinux Sodium CAS 114870-03-0 API
Supply with High Purity and Stable Quality
Chemical Name: Fondaparinux Sodium
CAS: 114870-03-0
An Antithrombotic Anticoagulant, a Factor Xa Inhibitor
API High Quality, Commercial Production
Chemical Name | Fondaparinux Sodium |
Synonyms | Methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(14)-O-β-D-glucopyranuronosyl-(14)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(14)-O-2-O-sulfo-α-L-idopyranuronosyl-(14)-2-deoxy-2-(sulfoamino)-α-D-glucopyranoside 6-(hydrogen sulfate) sodium salt |
CAS Number | 114870-03-0 |
Stock Status | In Stock, Production Scale Up to Hundreds of Kilograms |
Molecular Formula | C31H43N3O49S8.10Na |
Molecular Weight | 1728.08 |
Melting Point | >209℃(dec.) |
Storage Condition | 2~8℃ |
COA & MSDS | Available |
Origin | Shanghai, China |
Brand | Ruifu Chemical |
Item | Specifications |
Appearance | White to Off-White Powder |
Assay / Analysis Method | 95.0%~103.0% (on Dried Basis) |
Solubility | Freely Soluble in Water, 2.0M Sodium Chloride and 0.5M Sodium Hydroxide and Insoluble in Ethanol |
Identification 13C-NMR | Resonances for Fondaparinux Sodium should be observed at 58.2, 29.5, 60.5, 60.8, 68.9, 69.2, 69.6, 98.9, 100.4, 101.1, 102.4, 103.9, 176.7 and 178.0ppm. The Chemical shifts of these signals do not differ by more than ±0.3ppm other signals of variable heights and chemical shifts, attributable to Fondaparinux Sodium, maybe seen between 58.0~80.5 ppm and 98.7~104.5ppm |
Identification HPLC | The retention time of the major peak of the sample solution corresponds to that of the standard solution |
Identification AAS | Sodium should have characteristic absorption at 330.2nm under the determination of sodium |
pH | 6.0~8.0 |
Sodium (Na) | 11.5%~15.0% (Calculated on anhydrous and solvents free) |
Free Sulfate | ≤0.30% |
Residual Chloride | ≤1.00% |
Related Substances | |
Impurity A | ≤0.80% |
Impurity B | ≤0.60% |
Single Other Impurity | ≤0.30% |
Total Impurities | ≤2.00% |
Residual Solvents | |
Methanol | ≤3000ppm |
Ethanol | ≤5000ppm |
Ethyl Acetate | ≤5000ppm |
DMF | ≤880ppm |
Methylbenzene | ≤890ppm |
Pyridine | ≤50ppm |
Water Content (K.F) | ≤15.0% |
Bacterial Endotoxins | ≤3.3EU/mg |
Microbial Limit | The total number of Microorganisms ≤100cfu/g |
Test Standard | Enterprise Standard; United States Pharmacopoeia (USP) Standard |
Usage | API, An Antithrombotic Anticoagulant, a Factor Xa Inhibitor |
Package: Bottle, Aluminum foil bag, 25kg/Cardboard Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture
Fondaparinux Sodium (CAS 114870-03-0) is the first of a new class of an antithrombotic anticoagulant chemically related to low molecular weight heparins (LMWH). Fondaparinux sodium is a factor Xa inhibitor to form the high affinity binding site for the anti-coagulant factor antithrombin III (ATIII). Fondaparinux sodium binding at this site potentiates the natural inhibitory effect of ATIII against factor Xa by a factor of approximately 300, which results in inhibition of thrombin generation. It is marketed by GlaxoSmithKline. A generic version developed by Alchemia is marketed within the US by Dr. Reddy's Laboratories. Fondaparinux sodium was first introduced in the US for prophylaxis of deep vein thrombosis which may lead to pulmonary embolism following major orthopaedic surgery. This entirely synthetic molecule is a copy of the heparin pentasaccharide sequence, the shortest fragment able to catalyze antithrombin lllmediated inhibition of factor Xa thereby inhibiting thrombin generation without antithrombin action.